Drug Profile
Research programme: reverse targeting technologies - Roche/Aphoenix
Latest Information Update: 21 Feb 2017
Price :
$50
*
At a glance
- Originator Anadys Pharmaceuticals; Aphoenix
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 Dec 2005 This programme is still in active development
- 09 Sep 2004 Preclinical trials in Undefined in Japan (unspecified route)
- 09 Sep 2004 Preclinical trials in Undefined in USA (unspecified route)